Skip to main
BDTX
BDTX logo

BDTX Stock Forecast & Price Target

BDTX Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Black Diamond Therapeutics Inc has demonstrated promising initial Phase 2 results for its EGFR MasterKey inhibitor, BDTX-1535, showing a 36% overall response rate (ORR) among evaluable patients, which improved to 42% when excluding those without on-target resistance mutations. The majority of patients in the study, 74% of 19 patients, continued treatment as of the data cutoff, suggesting a favorable tolerability profile and potential for sustained responses. Additionally, the company is positioned within an underserved market for non-classical EGFR-mutant non-small cell lung cancer (NSCLC), providing a compelling rationale for further investment, as the current available therapies do not adequately address these specific oncogenic mutations.

Bears say

Black Diamond Therapeutics Inc faces significant risks related to the efficacy and safety of its lead candidate, BDTX-1535, which could adversely affect clinical outcomes and investor confidence. The company’s financial position reflects expected continued losses, with a projected full-year 2025 net loss of $1.32 per share, indicating a challenging path to profitability. Furthermore, the adjustments to near- to mid-term expense assumptions and potential dilution risks raise concerns about the sustainability of the company's operations and its ability to achieve commercialization milestones.

BDTX has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Black Diamond Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Black Diamond Therapeutics (BDTX) Forecast

Analysts have given BDTX a Strong Buy based on their latest research and market trends.

According to 9 analysts, BDTX has a Strong Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Black Diamond Therapeutics (BDTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.